Trial · NCT03049735
Adverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 60
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hot flush | Vascular disorders | Relugolix Plus E2/NETA (Group A) | 14 | 128 | 14 |
| other | Hot flush | Vascular disorders | Relugolix Plus Delayed E2/NETA (Group B) | 47 | 132 | 48 |
| other | Hot flush | Vascular disorders | Placebo (Group C) | 10 | 127 | 10 |
| other | Hypertension | Vascular disorders | Relugolix Plus E2/NETA (Group A) | 7 | 128 | 8 |
| other | Hypertension | Vascular disorders | Relugolix Plus Delayed E2/NETA (Group B) | 3 | 132 | 5 |
| other | Hypertension | Vascular disorders | Placebo (Group C) | 0 | 127 | 0 |
| other | Headache | Nervous system disorders | Relugolix Plus E2/NETA (Group A) | 14 | 128 | 15 |
| other | Headache | Nervous system disorders | Relugolix Plus Delayed E2/NETA (Group B) | 14 | 132 | 18 |
| other | Headache | Nervous system disorders | Placebo (Group C) | 19 | 127 | 20 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Relugolix Plus E2/NETA (Group A) | 4 | 128 | 6 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Relugolix Plus Delayed E2/NETA (Group B) | 7 | 132 | 8 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo (Group C) | 4 | 127 | 5 |
| other | Upper respiratory tract infection | Infections and infestations | Relugolix Plus E2/NETA (Group A) | 1 | 128 | 1 |
| other | Upper respiratory tract infection | Infections and infestations | Relugolix Plus Delayed E2/NETA (Group B) | 7 | 132 | 7 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo (Group C) | 3 | 127 | 4 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Relugolix Plus E2/NETA (Group A) | 1 | 128 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Relugolix Plus Delayed E2/NETA (Group B) | 0 | 132 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo (Group C) | 7 | 127 | 7 |
| serious | Avulsion fracture | Injury, poisoning and procedural complications | Relugolix Plus E2/NETA (Group A) | 1 | 128 | 1 |
| serious | Avulsion fracture | Injury, poisoning and procedural complications | Relugolix Plus Delayed E2/NETA (Group B) | 0 | 132 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03049735/events